Cargando…

Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine

Detalles Bibliográficos
Autores principales:	Ramírez-García, Almudena, Lozano Jiménez, Sara, Darnaude Ximénez, Ignacio, Gil Cacho, Alberto, Aguado-Noya, Ramón, Segovia Cubero, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. 2021
Materias:	Scientific Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282480/ https://www.ncbi.nlm.nih.gov/pubmed/34364831 http://dx.doi.org/10.1016/j.rec.2021.07.005

Ejemplares similares

Pericarditis tras la administración de la vacuna de ARNm BNT162b2 contra la COVID-19
por: Ramírez-García, Almudena, et al.
Publicado: (2021)

Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19
por: Bautista García, Javier, et al.
Publicado: (2021)

INCESSANT PERICARDITIS AND CARDIAC TAMPONADE FOLLOWING THE BNT162B2 MRNA COVID-19 VACCINE
por: Rodden, Diane, et al.
Publicado: (2022)

Improving BNT162b2 mRNA Vaccine Tolerability without Efficacy Loss by Pidotimod Supplementation
por: Ucciferri, Claudio, et al.
Publicado: (2022)

Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination
por: Goddard, Kristin, et al.
Publicado: (2022)

BNT162b2 mRNA Vaccine–Induced Immune Response in Oral Fluids and Serum
por: Seneviratne, Chaminda Jayampath, et al.
Publicado: (2022)

BNT162B2 MRNA BOOSTER VACCINE-RELATED PERICARDITIS: A CASE COMPLICATED BY PERICARDIAL AND PLEURAL EFFUSIONS
por: WHITE, ANESHA, et al.
Publicado: (2022)

Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines
por: Naveed, Zaeema, et al.
Publicado: (2022)

BNT162b2 mRNA Vaccine Interference with Co-Administration of Tdap Vaccine
por: Chilimuri, Sridhar, et al.
Publicado: (2021)

Prominent J Waves and Ventricular Fibrillation Caused by Myocarditis and Pericarditis After BNT162b2 mRNA COVID-19 Vaccination
por: Uesako, Hayata, et al.
Publicado: (2022)

The clinical course of patients with previous acute and recurrent pericarditis receiving the BNT162b2 vaccine
por: Wasserstrum, Yishay, et al.
Publicado: (2022)

Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines
por: Abraham, Natalia, et al.
Publicado: (2022)

Administration of BNT162b2 mRNA COVID-19 vaccine to subjects with various allergic backgrounds
por: Ribak, Yaarit, et al.
Publicado: (2023)

Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients
por: Sgherza, Nicola, et al.
Publicado: (2022)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Effusive–constrictive pericarditis after the second dose of BNT162b2 vaccine (Comirnaty): a case report
por: Viani, Giacomo Maria, et al.
Publicado: (2022)

Medium-term outcomes of myocarditis and pericarditis following BNT162b2 vaccination among adolescents in Hong Kong
por: Chua, Gilbert T., et al.
Publicado: (2022)

Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination
por: Katoto, Patrick D. M. C., et al.
Publicado: (2023)

Acute myocarditis following administration of BNT162b2 vaccine
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

The Peripheral Immune Landscape in a Patient with Myocarditis after the Administration of BNT162b2 mRNA Vaccine
por: Yoon, Bo Kyung, et al.
Publicado: (2022)

Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail populations
por: Campagna, Roberta, et al.
Publicado: (2022)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Acute adrenal insufficiency in a patient with panhypopituitarism after vaccination against COVID-19 (BNT162b2 Pfizer-BioNTech)
por: González López, Javier, et al.
Publicado: (2022)

Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada
por: Buchan, Sarah A., et al.
Publicado: (2023)

Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive
por: Kontopoulou, Konstantina, et al.
Publicado: (2021)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

BNT162b2 mRNA COVID-19 Vaccine: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
por: Terashima, Takeshi
Publicado: (2021)

Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
por: Gouda, Wesam, et al.
Publicado: (2022)

Central serous chorioretinopathy following the BNT162b2 mRNA vaccine
por: Hanhart, J., et al.
Publicado: (2022)

Addendum: Systems vaccinology of the BNT162b2 mRNA vaccine in humans
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

A Case of Exacerbation of Subclinical Hyperthyroidism after First Administration of BNT162b2 mRNA COVID-19 Vaccine
por: Yamamoto, Kana, et al.
Publicado: (2021)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia
por: Ab Rahman, Norazida, et al.
Publicado: (2023)

Vaccine Uptake in the US After Full Food and Drug Administration Approval of the BNT162b2 mRNA COVID-19 Vaccine
por: Bailey, Elise Vandersteen, et al.
Publicado: (2022)

Allergic reaction to anisakis-contaminated fish after the first administration of BNT162b2 mRNA vaccine: a case report
por: Harada, Fumiue, et al.
Publicado: (2022)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
por: Cocomazzi, Giovanna, et al.
Publicado: (2021)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
por: Payne, Rebecca P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fpjgk57kb5i8slji5cq0g9phus